Central Nervous System (CNS) Drug Development Strategy: What is the Role of External Investment in this High-Risk Disease Space?

SUMMARY In 2018, Pfizer announced its plan to stop R&D activity in the central nervous system disease space and to create a venture fund that will invest in biotech firms conducting innovative neuroscience research The strategy of investing in a therapeutic space exclusively via corporate capital is coming into greater…

Applying Technology in Pharma (ATP): Assessment of Investment Trends in Digital Health

SUMMARY VC investment in digital healthcare has been growing rapidly (+42% vs. 2017) as the potential of new technology to solve complex issues, ranging from providing healthcare services to managing chronic conditions, evolves Most of these VC-backed digital healthcare companies aim to provide technology-enhanced solutions for providers and patients with…

Do Cutting-Edge One-Time Treatments Need Equally Innovative Outcomes or Annuity Based Payment Models?

 Following years of hushed excitement and mounting anticipation in biotech circles, gene and cell therapies finally made the jump in 2017 from the safety of guarded clinical trial experimentation to broad availability to patients and their caregivers in the USA.  The USA’s FDA (Food and Drug Administration) approvals of the…

CAR-T Combos: Potentially the Next Big Thing in Solid Tumors, Yet Pricing ‘Sticker Shock’ is not the Only Hurdle to be Overcome

After years of anticipation, CAR-Ts (chimeric antigen receptor–T-cells) finally made the transition from being promising future therapies, to breakthrough marketed products in 2017. Novartis’s KYMRIAH™ got the FDA nod in late August for pediatric B-ALL (B-cell acute lymphoblastic leukemia), followed by Kite’s YESCARTA™ in October for NHL (Non-Hodgkin lymphoma) (Figure 1)….

WHO Stands to Benefit the most from the Biosimilars Prequalification Programme?

Most companies prioritise launching innovative therapies in high-income countries due to their greater ability and willingness to pay.  This greater funding opportunity allows for earlier adoption of innovative, high-value products, which help to fulfil commercial expectations and realise returns on their research and development investment.  As a result, these high-income…

Page 2 of 9123...Last »